Football Match Shooting: 11 Killed by Armed Group
- The Inflation Reduction act of 2022 granted Medicare the authority to negotiate prices for certain high-cost prescription drugs, marking a significant shift in U.S.
- For decades, Medicare was prohibited from directly negotiating drug prices with pharmaceutical companies, unlike many other developed countries.
- On August 29,2023,CMS announced the first 10 drugs selected for negotiation,with the initial negotiated prices taking effect on January 1,2024.
“`html
The Inflation Reduction Act and Prescription Drug Pricing
Table of Contents
The Inflation Reduction act of 2022 granted Medicare the authority to negotiate prices for certain high-cost prescription drugs, marking a significant shift in U.S. pharmaceutical policy. This negotiation process aims to lower drug costs for seniors and people with Medicare,and the first negotiated prices went into effect in 2024.
For decades, Medicare was prohibited from directly negotiating drug prices with pharmaceutical companies, unlike many other developed countries. This prohibition contributed to the high cost of prescription drugs in the United States.The Inflation Reduction Act changed this by allowing the Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), to select drugs for negotiation based on factors like high Medicare spending and lack of generic or biosimilar competition.
On August 29,2023,CMS announced the first 10 drugs selected for negotiation,with the initial negotiated prices taking effect on January 1,2024. These drugs treat conditions such as diabetes, heart failure, and blood clots. CMS estimates that these negotiations will lead to significant savings for Medicare beneficiaries.
How Drug Negotiation Works
The drug negotiation process under the Inflation Reduction Act involves several stages. First,CMS identifies eligible drugs based on specific criteria. Then,the agency engages in negotiations with the drug manufacturers. If an agreement isn’t reached, a manufacturer can face a tax or withdrawal of coverage for their drugs under Medicare and Medicaid.
The law prioritizes drugs that have been on the market for a certain period (generally, at least 7 years for small-molecule drugs and 11 years for biologics) to avoid hindering innovation. Negotiations occur annually, with additional drugs being added to the list over time. The Inflation Reduction Act outlines a phased implementation, with the number of drugs subject to negotiation increasing each year through 2029.
For example, in the first negotiation cycle, drugs like Eliquis (apixaban) for blood clots and Jardiance (empagliflozin) for diabetes were selected. Fierce Pharma reported on the initial list, detailing the potential impact on pharmaceutical companies.
Impact on Pharmaceutical Companies and Innovation
The Inflation Reduction Act’s drug pricing provisions have sparked debate regarding their potential impact on pharmaceutical innovation. Pharmaceutical companies, represented by organizations like the Pharmaceutical Research and Manufacturers of America (PhRMA), argue that price negotiation will reduce their revenues and, consequently, their ability to invest in research and advancement of new drugs.
PhRMA has filed lawsuits challenging the constitutionality of the drug negotiation provisions, arguing that they violate the Fifth Amendment’s takings clause. Reuters covered the legal challenges, noting the industry’s concerns about government interference in pricing decisions. However,proponents of the law contend that the negotiation process is carefully designed to balance affordability with continued innovation.
According to a RAND Corporation analysis, the impact on innovation is highly likely to be modest, with the law primarily affecting the profitability of drugs with limited competition.
Future of Drug Pricing Reform
The implementation of the Inflation Reduction Act’s drug pricing provisions is an ongoing process. The